Holen Sie sich die Stockscreener-App
1.25
14.63%
-0.22
Schlusskurs vom Vortag:
$1.47
Offen:
$1.45
24-Stunden-Volumen:
162.23K
Relative Volume:
6.85
Marktkapitalisierung:
$14.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-3.5909
EPS:
-0.3481
Netto-Cashflow:
-
1W Leistung:
-43.72%
1M Leistung:
-41.90%
6M Leistung:
-23.24%
1J Leistung:
-58.86%
1-Tages-Spanne:
$1.10
$1.45
1-Wochen-Bereich:
$1.10
$2.45
52-Wochen-Spanne:
$1.0775
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Firmenname
Akari Therapeutics Plc Adr
Sektor
Branche
Telefon
(646) 350-0702
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie AKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AKTX | 1.25 | 14.23M | 0 | 0 | 0 | -0.3481 |
| VRTX | 449.25 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.78 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.73 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-01-04 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Hochstufung | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Bestätigt | Chardan Capital Markets | Sell |
| 2016-07-11 | Eingeleitet | Chardan Capital Markets | Sell |
Alle ansehen
Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status | AKTX Stock News - StockTitan
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan
Akari Therapeutics shareholders approve Peak Bio merger - Investing.com
Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Akari Therapeutics PlcADR (AKTX) Price Target Increased by 45.45% to 81.60 - MSN
Akari Therapeutics appoints Rob Bazemore to board - Investing.com
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - StockTitan
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - StockTitan
Akari Therapeutics shareholders approve board and auditors - Investing.com India
Akari Therapeutics shareholders approve board and auditors By Investing.com - Investing.com India
Zoomcar announces departure of President Adarsh Menon By Investing.com - Investing.com
Phillips Edison expands board, appoints Devin Murphy By Investing.com - Investing.com India
Goldman Sachs raises Birkenstock target to $59.50, keeps neutral stance By Investing.com - Investing.com
Shopify’s market position 'promising for growth', Evercore ISI sees stock upside - Investing.com
Akari Therapeutics secures $7.6 million in private financing By Investing.com - Investing.com
Closing Figures Unveiled: Akari Therapeutics Plc ADR (AKTX) Drop -4.19, Closes at 1.72 – DWinneX - The Dwinnex
Arbe Robotics sees high demand for convertible debt By Investing.com - Investing.com
Insmed executive sells over $270k in company stock By Investing.com - Investing.com
Dialing Up Nights Out: Heineken® & Bodega Launch the No-Frills 'Boring Phone' | GlobeNewswire by notified - NTB Kommunikasjon
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 T - Benzinga
48 Stocks Moving In Friday's Mid-Day SessionAfya (NASDAQ:AFYA) - Benzinga
GCI: Best & Worst Performing Small Cap Stocks for July 19, 2019 - StockNews.com
52 Biggest Movers From YesterdayAyala Pharmaceuticals (OTC:ADXS), Altisource Asset Mgmt (AMEX:AAMC) - Benzinga
'Flying Whale' Blimp That Never Lands Joins Global Airship Race - Bloomberg
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% - Investing.com
22 Stocks Moving In Monday's Pre-Market SessionAkari Therapeutics (NASDAQ:AKTX), argenx (NASDAQ:ARGX) - Benzinga
Mid-Morning Market Update: Markets Fall; Initial Jobless Claims Drop to 259,000Akari Therapeutics (NAS - Benzinga
Dow Jones News: Dow Rallies 200 Points After Macron and Le Pen Win First Round of French Election - Money Morning
25 Stocks Moving In Tuesday's Pre-Market SessionAkari Therapeutics (NASDAQ:AKTX), Aurinia Pharmaceutic - Benzinga
Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher - Nasdaq
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
Lockheed Lands Airship Deal as Oil Industry Spurs Blimp Revival - Bloomberg
Two Stocks That Have Deerfield Management And Anchor Bolt Capital Excited - Insider Monkey
Finanzdaten der Akari Therapeutics Plc Adr-Aktie (AKTX)
Es liegen keine Finanzdaten für Akari Therapeutics Plc Adr (AKTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):